December 19, 2023 8:20am
Between “real” investor sentiment and actual cell and gene therapy sector pricing levels
Pre-open Indications: 1 Negative and 1 Positive Indications
Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors! Join me … in the NO spin zone.
Never leave an investor uninformed!
Remember that overnight action in a.m. futures and global markets doesn't necessarily translate into actual trading in the today’s market session.
One of my usual questions, are we facing a prisoner’s dilemma - a situation wherein algorithms acting with electronic trading interest do not achieve a continued optimal outcome for this sectors investor group.
The pre-open Dow futures are UP +0.22 % or (+80 points), the S&P is UP +0.19 or (+9 points) as the Nasdaq is UP +0.17% or (+29 points)
Stock futures were slightly higher Tuesday,
European markets were higher,
Asia Pacific markets were mixed, and most slightly higher.
Henry’omics:
We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …
Indexes achieved a barely upside move … the Dow closed UP +0.86 points or +0.00%, the S&P closed UP +21.37 points or +0.45% while the Nasdaq closed UP +90.89 points or +0.61%.
Economic Data Docket: building permits data for November and housing starts
- The Commerce Department is expected to release its third and final take on Q3 GDP on Thursday, to be followed by its broad-ranging Personal Consumption Expenditures (PCE) report on Friday, which will cover income growth, consumer spending, and crucially, inflation.
Monday, RegMed Investors (RMi) Closing Bell: “another downturn after a Friday downswing. We have to play the cards dealt.” … https://www.regmedinvestors.com/articles/13251
RegMed Investors (RMi): bluebird bio (BLUE) proposes $150 million stock offering … https://www.regmedinvestors.com/articles/13252
Q4: December – 6 positive and 6 negative closes
- November – 11 positives, 1 holiday and 10 negative closes
- October – 1 sick day, 9 positive and 12 negative closes
Companies in my headlights – It’s your decision; I provide ideas and context: looking for lost SHEAP …
I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.
Positive Indications:
Monday’s closing price, some Friday closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)
Sage Therapeutics (SAGE) closed down -$0.51 after Friday’s -$0.14 with a positive +$0.62 or +2.93% pre-open indication.
Negative Indication:
Monday’s closing price, some Friday closing “numbers” with aftermarket dollar ($) and cent ($0.00) value and percentage (%)
Intellia Therapeutics (NTLA) closed down -$0.43 after Friday’s +$1.47 with a negative -$0.25 or -0.82% pre-open indication
The BOTTOM LINE: I am getting ready to leave for the holiday, Christmas … Do not chase momentum after dramatic upside/downside equities, even as the market has run since late October; the risks of hiccups are rising!
Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!” If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-military officer and x-FBI, an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to our knowledge of price movements and questioning pricing targets.
It’s up to you to decide as … “Investors NEED to start formulating their portfolio outlook into next year.”
Dow:
- Up 3.8% for December
- Hit a new high during Monday’s session
- Up 12.6% for the year
S&P 500:
- Up 3.8% in December
- Up 23.5% in 2023
Nasdaq:
- Up 4.8% for the month
- Up 42.4% for the year and on pace for best yearly performance since 2020 <Samantha Subin, Chris Hayes, CNBC>
Monday post happening:
- The 10-year U.S. Treasury yield ticked higher to 3.95%. Meanwhile, oil prices extended their recent rebound, as West Texas intermediate futures settled at $73 a barrel.
It's time to think ahead to December. It's usually an important month for the Nasdaq.
- Reiterating, “There are signs of slowing in the U.S. economy. Layoff news has become more frequent, especially in technology, and so have business failures. The commercial and residential real estate markets have been weak all year. The question is if the real estate issues can damage the banking system, as in 2008, and derail the economy.” <The Street>
- One can also never discount geopolitical stresses.
- Don’t FORGET portfolio tax selling and a bit of rebalancing
- And then comes January and with worries that the U.S. economy will be slowing down, the potential for continued Middle East violence and, of course, the real prospect of bitterly contested elections across all of the United States. <The Street>
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.
